Dbv Technologies (NASDAQ: DBVT)
Dbv Technologies Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Dbv Technologies Company Info
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
News & Analysis
Why Shares of DBV Technologies Jumped Thursday
"The New England Journal of Medicine" reported phase 3 trial details regarding the company's peanut allergy treatment for toddlers.
Why DBV Technologies Stock Is Soaring Today
The company can now move forward with a late-stage study of its lead pipeline candidate.
Why DBV Technologies Stock Popped Again Today
The company kept its upward momentum going with news of nearly $200 million in fresh funding.
Why DBV Technologies Was a Big Winner on Wednesday
Its peanut allergy patch tests quite well in very young patients.
Why DBV Technologies Stock Is Down Sharply on Tuesday
The road ahead for the peanut allergy treatment Viaskin Peanut is going to be rockier than investors had hoped.
Why DBV Technologies Stock Is Jumping Today
The company plans to announce new data for its experimental peanut allergy drug this week.
Why DBV Technologies Stock Is Rising Today
The company released its latest quarterly update, and investors liked what they saw.
Why DBV Technologies Stock Popped Today
After it hit a major regulatory roadblock, DBV Technologies sees a path to approval for its leading candidate.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.